ESMO 2022 Prostate Cancer

Viewing 1-20 of 37 articles

ESMO 2022: Invited Discussant: Results of RADICALS-HD

ESMO 2022: Observations on the Biology of PSMA Implications for Targeting

ESMO 2022: Lu-PSMA for Prostate Cancer Treatment

ESMO 2022: PSMA Targeted T Cell Engagers

ESMO 2022: PSMA for Diagnosis and Staging

ESMO 2022: Duration of Androgen Deprivation Therapy with Post-Operative Radiotherapy for Prostate Cancer First Results of the RADICALS-HD Trial ISRCTN40814031

ESMO 2022: Development of Novel Treatments in Metastatic Prostate Cancer Discussion

ESMO 2022: Preliminary Phase 2 Results of the CYPIDES Study of ODM-208 in mCRPC Cancer Patients

ESMO 2022: Cabazitaxel Every 2 Weeks Versus Every 3 Weeks in Older Patients with mCRPC: The CABASTY Randomized Phase III Trial

ESMO 2022: Pembrolizumab + Olaparib Versus Abiraterone or Enzalutamide for Patients with Previously Treated mCRPC: Randomized Open-Label Phase 3 KEYLYNK-010 Study

ESMO 2022: IMPROVE Investigation of Metformin in Patients with mCRPC in Combination with Enzalutamide Versus Enzalutamide Alone: A Randomized, Open Label, Phase II Trial

ESMO 2022: Metastatic Castration-Sensitive Prostate Cancer 2022 Updates Discussion

ESMO 2022: Differential Treatment Response with Nodal Metastases in mHSPC and Evaluation of Nodal Burden as a Prognostic Biomarker -Ancillary Studies of the Docetaxel and Abiraterone Acetate and Prednisolone Phase III Trials from STAMPEDE

ESMO 2022: 8-Month PSA Strongly Predicts Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial

ESMO 2022: Quantity versus Quality of Life OR Quantity and Quality of Life Discussion

ESMO 2022: Duration of Androgen Suppression with Post-Operative Radiotherapy (DADSPORT): A Collaborative Meta-Analysis of Aggregate Data

ESMO 2022: Quality of Life and Patient-relevant Endpoints With Darolutamide in the Phase 3 ARASENS Study

ESMO 2022: Biopsy-Based Basal-Luminal Subtyping Classifier in High-Risk Prostate Cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Randomized Phase III Trials

ESMO 2022: Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide (ENZA) in Men Undergoing Active Surveillance (AS)

ESMO 2022: Detection of Mutations in Homologous Recombination Repair Genes in Tumour Tissue and Circulating Tumour DNA from Patients with Metastatic Castrate-Resistant Prostate Cancer in the Phase III PROpel Trial

1
2